ArticleFrontiers in neuroscience2025
Evaluating the efficacy of probiotics in treating Parkinson's disease model rats using magnetic resonance enhanced gradient echo T2-weighted angiography sequence.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) involves iron deposition in the substantia nigra (SN) and loss of dopaminergic neurons, with gut microbiota dysbiosis potentially affecting the brain iron via the gut-brain axis, whereas magnetic resonance enhanced gradient echo T2-weighted angiography (ESWAN) enables non-invasive iron assessment. Currently, for the detection of brain iron content, traditional tissue biopsy can provide accurate pathological information. However, its clinical and scientific research applications are limited owing to its invasiveness, difficulty in repeated operations, and other limitations. This study aimed to evaluate the therapeutic efficacy of probiotics and underlying mechanisms in PD rats using ESWAN. Methods: Twenty-seven male Sprague-Dawley rats were divided into control, PD model, and probiotic treatment groups. PD models were established by 6-hydroxydopamine stereotaxic injection into the SN, whereas the treatment group received oral gavage of Results: The probiotic treatment significantly reduced right SN R2* values ( Conclusion: This study provides experimental evidence that probiotics mitigate SN iron deposition in PD rats by regulating gut microbiota, highlighting ESWAN as a potential imaging biomarker for early PD diagnosis and therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.